uploads///ATNX

Athenex’s Product Groups and Geographic Performance

By

Updated

Revenues by product group

Athenex’s (ATNX) product groups include:

  • API (Active Pharmaceutical Ingredient) sales
  • medical device sales
  • contract manufacturing revenues
  • commercial product sales
  • license fees and consulting revenues
  • grant revenues

The majority of Athenex’s revenues in the first quarter came from API sales, commercial product sales, and license fees. Its API sales decreased from $3.0 million in the first quarter of 2017 to $2.64 million in the first quarter. 

Commercial product sales increased from $128,000 in the first quarter of 2017 to $9.14 million in the first quarter. License fees and consulting revenues showed the biggest increase, rising from $598,000 in the first quarter of 2017 to $25.01 million in the first quarter.

Article continues below advertisement

Sales of medical devices increased from $335,000 in the first quarter of 2017 to $585,000 in the first quarter. Contract manufacturing revenues decreased from $437,000 in the first quarter of 2017 to $241,000 in the first quarter. Its grant revenues increased from $83,000 in the first quarter of 2017 to $140,000 in the first quarter.

Geographic performance

Athenex generated a major part of its first-quarter revenues from three geographies—the United States, Spain, and Austria. Its US revenues jumped from $713,000 in the first quarter of 2017 to $9.9 million in the first quarter. 

The company’s revenues from Austria increased from $1.0 million in the first quarter of 2017 to $1.24 million in the first quarter. The company generated $25.0 million from Spain in the first quarter. In the first quarter of 2017, it didn’t generate any revenues from this region. 

Athenex’s first-quarter revenues from India and China totaled $962,000 and $648,000, respectively. In the first quarter of 2017, its revenues from India and China totaled $1.47 million and $312,000, respectively.

In the next part of the series, we’ll explore Athenex’s research pipeline.

Advertisement

More From Market Realist